ReNeuron Group plc Total Voting Rights (7068D)
01 Julio 2021 - 01:00AM
UK Regulatory
TIDMRENE
RNS Number : 7068D
ReNeuron Group plc
01 July 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that as at 30
June 2021, the Company had 56,936,402 ordinary shares in issue,
each carrying one voting right. This follows the issue 72,697 new
shares arising from the exercise of options by retired
non-executive directors, such shares having been admitted under the
Company's existing block listing arrangement.
As the Company holds no ordinary shares in treasury, the figure
of 56,936,402 may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking) +44 (0)20 3328 5656
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRMZGFVDGRGMZM
(END) Dow Jones Newswires
July 01, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024